Thermo Fisher Scientific Inc. (NYSE:TMO) is Baxter Bros Inc.’s 10th Largest Position

Baxter Bros Inc. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,188 shares of the medical research company’s stock after selling 19 shares during the quarter. Thermo Fisher Scientific makes up about 2.7% of Baxter Bros Inc.’s holdings, making the stock its 10th biggest holding. Baxter Bros Inc.’s holdings in Thermo Fisher Scientific were worth $16,742,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of TMO. Wealth Alliance Advisory Group LLC lifted its holdings in Thermo Fisher Scientific by 1.3% during the 2nd quarter. Wealth Alliance Advisory Group LLC now owns 1,536 shares of the medical research company’s stock valued at $775,000 after purchasing an additional 20 shares during the last quarter. McLean Asset Management Corp lifted its holdings in Thermo Fisher Scientific by 2.2% during the 2nd quarter. McLean Asset Management Corp now owns 928 shares of the medical research company’s stock valued at $483,000 after purchasing an additional 20 shares during the last quarter. Avestar Capital LLC lifted its holdings in Thermo Fisher Scientific by 2.9% during the 2nd quarter. Avestar Capital LLC now owns 700 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 20 shares during the last quarter. Dumont & Blake Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 0.8% in the second quarter. Dumont & Blake Investment Advisors LLC now owns 2,649 shares of the medical research company’s stock worth $1,336,000 after acquiring an additional 21 shares during the last quarter. Finally, EPG Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 2.9% in the second quarter. EPG Wealth Management LLC now owns 746 shares of the medical research company’s stock worth $376,000 after acquiring an additional 21 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Shares of Thermo Fisher Scientific stock traded down $1.56 on Monday, hitting $595.24. The company had a trading volume of 64,845 shares, compared to its average volume of 1,603,731. The firm has a market capitalization of $234.18 billion, a P/E ratio of 27.56, a P/E/G ratio of 1.33 and a beta of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $412.80 and a twelve month high of $609.30. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.78 and a quick ratio of 2.11. The stock has a 50-day moving average of $545.24 and a 200-day moving average of $496.53.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 28th. The medical research company reported $5.60 EPS for the quarter, topping the Zacks’ consensus estimate of $5.51 by $0.09. The business had revenue of $9.27 billion for the quarter, compared to analyst estimates of $8.75 billion. Thermo Fisher Scientific had a net margin of 22.47% and a return on equity of 29.43%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 22.07 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 15th. Stockholders of record on Wednesday, September 15th will be given a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.17%. The ex-dividend date of this dividend is Tuesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 5.32%.

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, August 4th. The shares were sold at an average price of $539.05, for a total value of $5,390,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jim P. Manzi sold 572 shares of the stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $536.54, for a total transaction of $306,900.88. The disclosure for this sale can be found here. Insiders own 0.44% of the company’s stock.

A number of equities analysts have weighed in on TMO shares. Citigroup boosted their target price on shares of Thermo Fisher Scientific from $535.00 to $620.00 and gave the stock a “neutral” rating in a research note on Monday. SVB Leerink boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock an “outperform” rating in a research note on Monday. Benchmark began coverage on shares of Thermo Fisher Scientific in a research report on Friday, July 16th. They set a “buy” rating and a $580.00 price target for the company. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “hold” rating to a “strong sell” rating and set a $491.00 price target for the company. in a research report on Monday, July 12th. Finally, BTIG Research lifted their price target on shares of Thermo Fisher Scientific from $590.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, July 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $575.19.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Featured Article: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.